The shares of this small-cap company, which is a fast-moving consumer healthcare organization, are in focus in the day’s trade, followed by an open offer to acquire it for Rs. 2,983 Crores.
Price Movement
With a market capitalization of Rs 11,473 crore, the shares of Sanofi Consumer Healthcare India Ltd made a 52-week high of Rs 5,375.00 per share, down by 7.2 percent from its current market price of Rs 4,982.10 per share. The stock has given a positive return of 3.08 percent over the last six months.
About the announcement
Opal Bidco SAS and Clayton, Dubilier & Rice Fund XII, L.P. have made an open offer to purchase up to 59.88 lakh Sanofi Consumer Healthcare India Ltd’s equity shares, representing 26 percent for Rs 4,982.05 per share.
This is an all-cash bid of Rs 2,983.23 crore based on full acceptance and is part of a worldwide control transition after Sanofi agreed to sell Opella Healthcare SAS, which indirectly holds a 60.40 percent stake in Sanofi Consumer Healthcare India.
The period of tender is from April 25 to May 9, 2025, and the payment date is May 26. After the deal, Clayton, Dubilier & Rice Fund XII, L.P. will have 50 percent of Opal Bidco SAS, Sanofi 48%, and Bpifrance 2 percent. All regulatory clearances are already in hand, and the transaction will create a world consumer healthcare leader headquartered in France.
Financial Highlights
The company reported a consolidated revenue of Rs 171 crore in Q3 FY25, up by 6.8 percent, from its Q3 FY24 revenue of Rs 160 crore. It posted a net profit of Rs 44 crore in Q3 FY25, down by 2.2 percent, from its Q3 FY24 net profit of Rs 45 crore. It has a P/E of 57x, which is higher than the industry P/E ratio of 49.28x.
About the Company
Sanofi Consumer Healthcare India Limited, which was incorporated in the year 2023 and has its headquarters located in Mumbai, is a fast-moving consumer healthcare organization and a subsidiary of Sanofi India Limited. Its products are marketed in the field of allergy, pain care, and physical well-being under brands such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU. These are marketed through wholesalers, government agencies, hospitals, pharmacies, and online platforms.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
